Efficacy of paclitaxel plus TS1 against previously treated EGFR mutated non-small cell lung cancer

Yen Han Tseng, Jen Fu Shih, Heng Sheng Chao, Yuh Min Chen

Research output: Contribution to journalArticle

Abstract

Background. Later line chemotherapy (≥2nd lines) such as Docetaxel or immunother- apy is frequently used. As the life expectancy of lung cancer patients is getting longer, we need to provide more treatment options. Other treatment options are not well documented except for Doxetaxel and immunotherapy. Therefore, the efficacy of paclitaxel plus TS1 (TTS1) is warranted. Methods. We retrospectively reviewed the chart records of our non-small cell lung cancer patients who were treated between 2010 and 2013. Clinical characteristics, type of tumor, EGFR mutation status, and treatment response to first-line EGFR-TKI therapy and efficacy of TTS1, were collected. Results. Twenty eight patients were enrolled in this study. No patients archived complete response and seven patients had partial response (ORR: 25%). The disease control rate was 60.7% (17/28). The progression free survival (PFS) was 4.0 months and overall survival (OS) was 15.8 months. Of them, 17 had EGFR mutations, eight EGFR wild type, and three were unknown EGFR status. After TTS1 treatment, patients with EGFR mutations had better PFS (4.9 months vs. 1.8 months) and OS (15.5 months vs. 7.2 months) compared with those of EGFR wild type. Conclusions. TTS1 are effective later line chemotherapy, especially in tumor EGFR mutated patients. Paclitaxel plus TS1 is another treatment of choice for NSCLC patients before a more effective treatment strategy is found.

Original languageEnglish
Article numbere7767
JournalPeerJ
Volume2019
Issue number9
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

paclitaxel
Chemotherapy
docetaxel
lung neoplasms
Paclitaxel
Non-Small Cell Lung Carcinoma
Tumors
Cells
Patient treatment
Disease control
cells
immunotherapy
mutation
Immunotherapy
Mutation
Therapeutics
drug therapy
Disease-Free Survival
Drug Therapy
neoplasms

Keywords

  • Epidermal growth factor receptor (EGFR)
  • Non-small cell lung cancer
  • TS1

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Efficacy of paclitaxel plus TS1 against previously treated EGFR mutated non-small cell lung cancer. / Tseng, Yen Han; Shih, Jen Fu; Chao, Heng Sheng; Chen, Yuh Min.

In: PeerJ, Vol. 2019, No. 9, e7767, 01.01.2019.

Research output: Contribution to journalArticle

Tseng, Yen Han ; Shih, Jen Fu ; Chao, Heng Sheng ; Chen, Yuh Min. / Efficacy of paclitaxel plus TS1 against previously treated EGFR mutated non-small cell lung cancer. In: PeerJ. 2019 ; Vol. 2019, No. 9.
@article{208f1514ad374d2995ba4c806e39e59c,
title = "Efficacy of paclitaxel plus TS1 against previously treated EGFR mutated non-small cell lung cancer",
abstract = "Background. Later line chemotherapy (≥2nd lines) such as Docetaxel or immunother- apy is frequently used. As the life expectancy of lung cancer patients is getting longer, we need to provide more treatment options. Other treatment options are not well documented except for Doxetaxel and immunotherapy. Therefore, the efficacy of paclitaxel plus TS1 (TTS1) is warranted. Methods. We retrospectively reviewed the chart records of our non-small cell lung cancer patients who were treated between 2010 and 2013. Clinical characteristics, type of tumor, EGFR mutation status, and treatment response to first-line EGFR-TKI therapy and efficacy of TTS1, were collected. Results. Twenty eight patients were enrolled in this study. No patients archived complete response and seven patients had partial response (ORR: 25{\%}). The disease control rate was 60.7{\%} (17/28). The progression free survival (PFS) was 4.0 months and overall survival (OS) was 15.8 months. Of them, 17 had EGFR mutations, eight EGFR wild type, and three were unknown EGFR status. After TTS1 treatment, patients with EGFR mutations had better PFS (4.9 months vs. 1.8 months) and OS (15.5 months vs. 7.2 months) compared with those of EGFR wild type. Conclusions. TTS1 are effective later line chemotherapy, especially in tumor EGFR mutated patients. Paclitaxel plus TS1 is another treatment of choice for NSCLC patients before a more effective treatment strategy is found.",
keywords = "Epidermal growth factor receptor (EGFR), Non-small cell lung cancer, TS1",
author = "Tseng, {Yen Han} and Shih, {Jen Fu} and Chao, {Heng Sheng} and Chen, {Yuh Min}",
year = "2019",
month = "1",
day = "1",
doi = "10.7717/peerj.7767",
language = "English",
volume = "2019",
journal = "PeerJ",
issn = "2167-8359",
publisher = "PeerJ Inc.",
number = "9",

}

TY - JOUR

T1 - Efficacy of paclitaxel plus TS1 against previously treated EGFR mutated non-small cell lung cancer

AU - Tseng, Yen Han

AU - Shih, Jen Fu

AU - Chao, Heng Sheng

AU - Chen, Yuh Min

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background. Later line chemotherapy (≥2nd lines) such as Docetaxel or immunother- apy is frequently used. As the life expectancy of lung cancer patients is getting longer, we need to provide more treatment options. Other treatment options are not well documented except for Doxetaxel and immunotherapy. Therefore, the efficacy of paclitaxel plus TS1 (TTS1) is warranted. Methods. We retrospectively reviewed the chart records of our non-small cell lung cancer patients who were treated between 2010 and 2013. Clinical characteristics, type of tumor, EGFR mutation status, and treatment response to first-line EGFR-TKI therapy and efficacy of TTS1, were collected. Results. Twenty eight patients were enrolled in this study. No patients archived complete response and seven patients had partial response (ORR: 25%). The disease control rate was 60.7% (17/28). The progression free survival (PFS) was 4.0 months and overall survival (OS) was 15.8 months. Of them, 17 had EGFR mutations, eight EGFR wild type, and three were unknown EGFR status. After TTS1 treatment, patients with EGFR mutations had better PFS (4.9 months vs. 1.8 months) and OS (15.5 months vs. 7.2 months) compared with those of EGFR wild type. Conclusions. TTS1 are effective later line chemotherapy, especially in tumor EGFR mutated patients. Paclitaxel plus TS1 is another treatment of choice for NSCLC patients before a more effective treatment strategy is found.

AB - Background. Later line chemotherapy (≥2nd lines) such as Docetaxel or immunother- apy is frequently used. As the life expectancy of lung cancer patients is getting longer, we need to provide more treatment options. Other treatment options are not well documented except for Doxetaxel and immunotherapy. Therefore, the efficacy of paclitaxel plus TS1 (TTS1) is warranted. Methods. We retrospectively reviewed the chart records of our non-small cell lung cancer patients who were treated between 2010 and 2013. Clinical characteristics, type of tumor, EGFR mutation status, and treatment response to first-line EGFR-TKI therapy and efficacy of TTS1, were collected. Results. Twenty eight patients were enrolled in this study. No patients archived complete response and seven patients had partial response (ORR: 25%). The disease control rate was 60.7% (17/28). The progression free survival (PFS) was 4.0 months and overall survival (OS) was 15.8 months. Of them, 17 had EGFR mutations, eight EGFR wild type, and three were unknown EGFR status. After TTS1 treatment, patients with EGFR mutations had better PFS (4.9 months vs. 1.8 months) and OS (15.5 months vs. 7.2 months) compared with those of EGFR wild type. Conclusions. TTS1 are effective later line chemotherapy, especially in tumor EGFR mutated patients. Paclitaxel plus TS1 is another treatment of choice for NSCLC patients before a more effective treatment strategy is found.

KW - Epidermal growth factor receptor (EGFR)

KW - Non-small cell lung cancer

KW - TS1

UR - http://www.scopus.com/inward/record.url?scp=85074116079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074116079&partnerID=8YFLogxK

U2 - 10.7717/peerj.7767

DO - 10.7717/peerj.7767

M3 - Article

AN - SCOPUS:85074116079

VL - 2019

JO - PeerJ

JF - PeerJ

SN - 2167-8359

IS - 9

M1 - e7767

ER -